Loading patent…
AssigneeTechnology Commercialization Corp.
InventorsBoris Vladimirovich Krylov, Ilya Vyacheslavovich Rogachevsky, Vera Borisovna Plakhova
Estimating the term…
A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
A method for treatment of pain in a subject in need thereof comprising a step of modulating a slow sodium channel signaling pathway involving ligand-receptor binding in the opioid or opioid-like receptor site area and a tetrodotoxin-resistant slow sodium channel known as NaV1.8, wherein said step is performed by in-vivo administration of a substance comprising a pharmaceutically acceptable carrier and a gamma-pyrone, said gamma-pyrone having a molecule with a carboxy group in position 2 of the pyranone ring and a carbonyl group in position 4 of the pyranone ring, said gamma-pyrone molecule further having a substituent in position 5 capable of participating in Ca2+ chelation, said substance is administered in a dosage containing from about 0.05 mg to about 100 mg of said gamma-pyrone.
Dependencies are inferred from the claim text.